Bridging the Gap: Immuno-biology of Radiotherapy and Clinical Trial Concepts

When:  Nov 3, 2017 from 07:30 to 10:00 (PT)

A joint session supported by The Radiosurgery Society and Society for Immunotherapy of Cancer

The intrinsic genotype and phenotype structured tumor microenvironment keeps host immune surveillance in evasion. Recent advances in cancer immunology led to understand the mechanism of immune evasion by targeting the checkpoint expression proteins in tumors and T-cells. This breakthrough led to the development of checkpoint blockade therapy that resulted in several clinical trials including combining with radiation for various disease sites and yielded promising results. Combination trials with radiation plus immunotherapy showed mixed and dismal results as we are still learning from pre-clinical data and clinical trials. The purpose of this symposium is to provide an opportunity to the members of radiation oncology community to understand cancer immunotherapy concepts, role of radiation changing the immune tumor microenvironment, understanding such radiation-induced immune modulating effects in a specific site disease and required rules in developing clinical trials that involves radiation and immunotherapy.

Co-Chairs: Mansoor M. Ahmed (NCI) and Samir Khleif (GRU)

Please note: This session is part of the Radiosurgery Society Annual Scientific Meeting taking place November 2 - 4, 2017.

Location

The Rio Hotel
3700 West Flamingo Dr.
Las Vegas, NV 89103